MDT
HealthcareMedtronic
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2013–2025(13yr)| Metric | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.6B | $17.0B | $20.3B | $28.8B | $29.7B | $30.0B | $30.6B | $28.9B | $30.1B | $31.7B | $31.2B | $32.4B | $33.5B | +3.6% |
| Gross Profit | $12.5B | $12.7B | $14.0B | $19.7B | $20.4B | $20.9B | $21.4B | $19.5B | $19.6B | $21.5B | $20.5B | $21.1B | $21.9B | +3.6% |
| Gross Margin | 75.1% | 74.5% | 68.9% | 68.3% | 68.7% | 69.8% | 70.0% | 67.4% | 65.2% | 68.0% | 65.7% | 65.3% | 65.3% | -0.0pp |
| Operating Income | $4.4B | $3.8B | $3.8B | $5.3B | $5.3B | $6.7B | $6.3B | $4.8B | $4.5B | $5.8B | $5.5B | $5.1B | $6.0B | +15.8% |
| Operating Margin | 26.5% | 22.4% | 18.6% | 18.4% | 17.9% | 22.2% | 20.5% | 16.6% | 14.9% | 18.2% | 17.6% | 15.9% | 17.8% | +1.9pp |
| Net Income | $3.5B | $3.1B | $2.7B | $3.5B | $4.0B | $3.1B | $4.6B | $4.8B | $3.6B | $5.0B | $3.8B | $3.7B | $4.7B | +26.8% |
| Net Margin | 20.9% | 18.0% | 13.2% | 12.3% | 13.6% | 10.4% | 15.2% | 16.6% | 12.0% | 15.9% | 12.0% | 11.4% | 13.9% | +2.5pp |
| Free Cash Flow | — | $4.6B | $4.3B | $4.2B | $5.6B | $3.6B | $5.9B | $6.0B | $4.9B | $6.0B | $4.6B | $5.2B | $5.2B | -0.3% |
| FCF Margin | — | 26.8% | 21.4% | 14.5% | 18.9% | 12.1% | 19.2% | 20.8% | 16.2% | 18.9% | 14.7% | 16.1% | 15.5% | -0.6pp |
| EPS (Diluted) | $3.37 | $3.02 | $2.41 | $2.48 | $2.89 | $2.27 | $3.41 | $3.54 | $2.66 | $3.73 | $2.82 | $2.76 | $3.61 | +30.8% |
1. THE BIG PICTURE
Medtronic is attempting to pivot from a legacy hardware manufacturer to an AI-integrated technology leader, recently achieving 8.7% quarterly revenue growth—its best performance in ten quarters (8-K). However, this acceleration is fighting against a heavy debt load and a valuation that suggests the market views its long-term prospects as stagnant compared to more agile peers like Boston Scientific or Intuitive Surgical.
2. WHERE THE RISKS HIT HARDEST
Medtronic’s "Innovation-driven growth" is threatened by "Alternative therapies such as GLP-1s" because these non-device treatments could reduce the patient pool for its core metabolic and cardiovascular offerings (10-K Item 1A). Furthermore, its "Scale and Presence" advantage is undermined by "Manufacturing and Supply Chain" vulnerabilities, specifically its reliance on sole-source suppliers and third-party sterilization services, which can lead to launch delays and lost sales (10-K Item 1A). Finally, the "technological leadership" management seeks is constantly at risk of "technological obsolescence" in a market where competitors frequently introduce disruptive or reprocessed products (10-K Item 1).
3. WHAT THE NUMBERS SAY TOGETHER
The numbers reveal a company that is growing faster than its recent history suggests but remains an efficiency laggard. While Q3 revenue jumped 8.7%, TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter growth sits at just 3.6%, the lowest in its peer group (XBRL). This divergence suggests the recent "highest enterprise revenue growth in 10 quarters" may be a cyclical peak driven by a cluster of new product launches—such as the Evolut FX+ or Micra system—rather than a permanent structural shift in the business mix (8-K).
Despite the sales pop, Medtronic’s FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin of 15.6% is the lowest among its peers, and its 4.9x net leverage is significantly higher than competitors like Abbott or Intuitive Surgical (XBRL). Short interest is low at 1.4% of float, indicating that while investors are skeptical of growth, there is no active bet on a collapse.
4. IS IT WORTH IT AT THIS PRICE?
At 14.8x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Medtronic trades at a modest discount to the peer median of 19.4x. The market is pricing in a long-term growth rate of just 1.7% (CAPM analysis). This low bar seems achievable given the 5.5% organic growth guidance for 2026, but the discount is justified by Medtronic's trailing revenue growth (+3.6%) and FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margins (15.6%), both of which rank last among its six-company peer group (XBRL). Investors are essentially paying for a 3.1% dividend yield—the highest in the group—while accepting the risk of a $26.7 billion net debt pile (XBRL).
5. WHAT WOULD CHANGE THIS VIEW?
- Cautious if FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margins continue to trail peers, suggesting that the "G&A leverage" mentioned by the CFO is failing to offset manufacturing costs (8-K).
- Constructive if organic revenue growth exceeds the 5.5% guidance for multiple quarters, proving that the innovation pipeline in Cardiovascular and Diabetes has structural staying power (8-K).
- Cautious if net debt/FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders leverage rises further, as this would limit Medtronic's ability to execute the "M&AM&AMergers & Acquisitions — the buying, selling, or combining of companies and venture strategy" management cites as a primary growth driver (8-K).
6. BOTTOM LINE
Structural Advantage: Global scale and a massive installed base of implanted devices that create high clinical evidence requirements and switching costs for competitors. Bottom Line: Medtronic is a high-yield value play for those who believe its recent growth spurt will eventually fix its lagging margins and heavy debt.
1. Top 5 Material Risks
- Competitive Landscape: Medtronic operates in over 150 countries against a range of competitors, from large diversified firms to niche manufacturers. Medtronic faces risks from technological obsolescence, the introduction of generic or reprocessed products, and alternative therapies such as GLP-1s.
- Manufacturing and Supply Chain: Medtronic relies on complex global manufacturing and third-party services, such as sterilization. Disruptions—caused by component shortages (e.g., semiconductors and resins), sole-source dependencies, or natural disasters—can lead to launch delays and lost sales.
- Regulatory Compliance: Medtronic is subject to rigorous oversight by the U.S. FDA and other global agencies. Failure to comply with manufacturing, labeling, or marketing regulations can result in warning letters, consent decrees, product seizures, or bans.
- Product Quality and Liability: Given the nature of implanted medical devices, quality failures can lead to recalls, safety alerts, and significant product liability litigation, which may damage the Medtronic brand and diminish market demand.
- Reimbursement and Healthcare Policy: Medtronic’s revenue depends on the ability of customers (hospitals and physicians) to obtain reimbursement from third-party payors. Legislative or administrative reforms aimed at cost-containment, such as national tender pricing, directly impact the prices Medtronic can charge.
2. Company-Specific Risks
- Diabetes Business Separation: Medtronic faces execution risks and potential failure to realize expected strategic benefits from the planned separation of its Diabetes business.
- Intellectual Property Litigation: Medtronic is frequently involved in intellectual property disputes as both plaintiff and defendant, which can result in significant damage awards, royalty obligations, or injunctions preventing the sale of specific products.
- Tax Litigation: Medtronic is currently involved in a dispute with the IRS regarding the allocation of income between Medtronic, Inc. and its Puerto Rico manufacturing subsidiary for fiscal years 2005 and 2006, which could have a material adverse impact on financial condition.
- Irish Jurisdiction: As an Irish-incorporated company, Medtronic is subject to Irish law, which differs from U.S. law regarding shareholder rights and the enforcement of U.S. court judgments, potentially limiting the ability of shareholders to protect their interests.
3. Regulatory/Legal Risks
- Anti-Corruption Laws: Medtronic is subject to the U.S. FCPA, the U.K. Bribery Act, and similar laws. Because many customers outside the U.S. are government-administered healthcare systems, Medtronic faces heightened risk regarding improper payments to government officials.
- Data Privacy and Cybersecurity: Medtronic is subject to various global privacy and cybersecurity laws. A breach or cyber-attack could result in regulatory sanctions, civil litigation, and significant operational disruption.
- Economic Sanctions: Medtronic’s international operations are subject to OFAC and BIS regulations. While business in countries subject to comprehensive sanctions (e.g., Iran, Syria, Cuba, Russia, Belarus) represents an insignificant portion of revenue, violations could lead to fines, debarment from government contracts, or loss of export privileges.
- Environmental Regulations: Medtronic must comply with laws regarding hazardous substances (e.g., EtOs and PFAS) and end-of-life disposal. Violations can lead to facility shutdowns, fines, and remediation costs.
4. Financial Impact Map
Competitive Pricing Pressure → Revenue → Declining reimbursement rates and national tender pricing (e.g., in China) impact the prices customers are willing to pay. Manufacturing/Supply Chain Disruptions → Cost of Goods Sold / Gross Margin → Volatile commodity prices, tariffs, and the need for alternative sourcing increase operational costs and risk lost sales. Product Quality/Recalls → Operating Expenses / Reputation → Recalls and safety alerts result in unanticipated costs and diminished market acceptance of the Medtronic brand. Intellectual Property Litigation → Net Income / Cash Flow → Potential for significant monetary damages, royalty payments, or injunctions preventing the sale of products. Tax Litigation (IRS Dispute) → Financial Condition / Tax Provision → An adverse outcome regarding the allocation of income between Medtronic, Inc. and its Puerto Rico subsidiary could materially affect financial results.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-Q | Feb 2026 | Jan 2026 |
| 8-K | Feb 2026 | — |
| 14A | Aug 2025 | — |
| 10-K | Jun 2025 | Apr 2025 |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Medtronic Stealth AXiS surgical system receives expanded FDA clearance for cranial and ENT procedures
- ▸FDA cleared Stealth AXiS for cranial and ENT procedures
- ▸System unifies AI-enabled planning, navigation, and robotics on single platform
- ▸Projects $42.1B revenue and $6.5B earnings by 2029
- ▸Requires 5.9% annual revenue growth to meet long-term targets
- ▸Expanded indication for OmniaSecure defibrillation lead also announced
Medtronic partners with Merit Medical to distribute ViaVerte nerve ablation system
- ▸Medtronic enters distribution agreement for FDA-cleared ViaVerte BVNA system
- ▸ViaVerte system offers minimally invasive treatment for chronic vertebrogenic lower back pain
- ▸System availability for ViaVerte expected in 2026
- ▸Global BVNA market projected to reach $1.56B by 2033
- ▸Merit Medical continues as supplier for Medtronic Kyphon product line
Medtronic receives FDA approval for expanded OmniaSecure defibrillation lead indication
- ▸FDA approved OmniaSecure lead for left bundle branch area conduction system pacing
- ▸OmniaSecure pacing mimics natural heart physiology for improved cardiac resynchronization
- ▸Acquiring Scientia Vascular for $550M; deal expected to close H1 FY27
- ▸Q3 EPS $1.36 beat consensus estimate of $1.34
- ▸Q3 revenue $9.02B exceeded expectations of $8.89B with 6% organic growth
Medtronic Q3 revenue $9.02B +8.7% YoY, adjusted EPS $1.36 beats estimates
- ▸Q3 revenue $9.02B, up 8.7% YoY and 6% organically
- ▸Adjusted EPS $1.36, down 2.2% YoY but beat estimates by 2.07%
- ▸Cardiovascular segment revenue $3.46B, up 10.6% organically
- ▸Diabetes segment revenue $796M, up 8.3% organically
- ▸Gross margin contracted 265 bps to 63.8% due to rising product costs
Medtronic to acquire Scientia Vascular for $550 million to expand neurovascular portfolio
- ▸Acquisition price $550 million plus additional milestone-based payments
- ▸Scientia Vascular specializes in guidewires and catheters for complex brain vessel navigation
- ▸Deal expected to close in first half of FY27
- ▸Transaction minimally dilutive to adjusted EPS in FY27, accretive thereafter
- ▸Acquisition strengthens Medtronic's position in hemorrhagic and acute ischemic stroke procedures